Skip to main content
PHASinactive

PhaseBio Pharmaceuticals Inc

Biopharma developer (SEC filing verified)·Phase 3
Cardiovascular

PHAS evidence brief

What we can confirm

BioSniper Score:
6.6 / 10
Lead Asset:
bentracimab (Phase 3)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.6 / 10 · Lead Asset: bentracimab (Phase 3)
BioSniper AIPage evidence connected

Prepared research question

What matters most for PHAS—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.6/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

bentracimab (Phase 3)

Next Catalyst

—

Tracking 2 pipeline candidates for PhaseBio Pharmaceuticals Inc.

Run PhaseBio Pharmaceuticals Inc through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available PhaseBio Pharmaceuticals Inc facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is PhaseBio Pharmaceuticals Inc's lead drug candidate?

PhaseBio Pharmaceuticals Inc's most advanced tracked candidate is bentracimab (Phase 3) for Reversal of antiplatelet activity of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure.

What therapeutic areas does PhaseBio Pharmaceuticals Inc focus on?

PhaseBio Pharmaceuticals Inc develops therapies across Cardiovascular.

923 companies304,840 SEC filings22,636 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.